Zura Bio Ltd. is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company focuses on advancing a pipeline that includes tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF, currently in Phase 2 trials such as TibuSHIELD for moderate to severe hidradenitis suppurativa and TibuSURE for systemic sclerosis. Additional assets include crebankitug (ZB-168) and torudokimab (ZB-880), which have completed Phase 1/Ib studies and are Phase 2 ready, targeting a portfolio of therapeutic indications to demonstrate efficacy, safety, and dosing convenience. Zura Bio Ltd. employs a dual antagonism strategy to address the heterogeneity of autoimmune diseases by simultaneously targeting multiple pathways, potentially offering improved treatment outcomes for underserved patients. Led by biotechnology entrepreneurs and pharmaceutical professionals, the company operates in the immunology sector, contributing to the development of innovative medicines for serious immune system disorders.